La información sobre este estudio está en inglés.

Si necesita ayuda en español, comuníquese con el Centro de Educación y Referencias sobre la Enfermedad de Alzheimer y las Demencias Relacionadas (ADEAR, por sus siglas en inglés) por teléfono al 800-438-4380 o envíe un correo electrónico. También puede llamar o enviar un correo electrónico al contacto del estudio (en inglés) para obtener información adicional.

Find more clinical trials

Sensory Stimulation to Improve Brain Function (Overture Study)

Start: April 24, 2018
End: September 2021
Enrollment: 60

What Is This Study About?

The Overture Study is a Phase I/II clinical trial to study safety, adherence rates, and efficacy of the Active GammaSense Stimulation System in older adults with mild cognitive impairment (MCI) and Alzheimer's disease. The device provides noninvasive auditory and visual sensory stimulation to the brain.

Do I Qualify To Participate in This Study?

Minimum Age: 55 Years

Maximum Age: N/A

Must have:

Mini-Mental State Examination Score of 14 to 26
Early Alzheimers disease, Alzheimers disease, or MCI due to Alzheimers disease
Participation of a caregiver

Must NOT have:

Profound hearing or visual impairment
Seizure disorder
Use of memantine (Namenda or Namzaric)
Implantable devices that are not compatible with magnetic resonance imaging

If I Qualify, Who Do I Contact?

Contact study personnel listed either under the general study contact or the location nearest you.

Need Help?

Contact NIA’s Alzheimer’s and related Dementias Education and Referral (ADEAR) Center at 800-438-4380 or email ADEAR.

Where Is This Study Located?

Who Sponsors This Study?

Lead: Cognito Therapeutics, Inc.

Source: ClinicalTrials.gov ID: NCT03556280